Cargando…

The impact of abdominal pain on global measures in patients with chronic idiopathic constipation, before and after treatment with linaclotide: a pooled analysis of two randomised, double-blind, placebo-controlled, phase 3 trials

BACKGROUND: Few clinical trials in chronic idiopathic constipation (CIC) patients have evaluated abdominal symptom severity and whether CIC patients with abdominal symptoms respond similarly to patients with limited abdominal symptoms. AIMS: To examine abdominal symptom severity and relationships be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, L, Lembo, A J, Lavins, B J, Shiff, S J, Hao, X, Chickering, J G, Jia, X D, Currie, M G, Kurtz, C B, Johnston, J M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2014
Materias:	Linaclotide for Constipation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4278547/ https://www.ncbi.nlm.nih.gov/pubmed/25312449 http://dx.doi.org/10.1111/apt.12985

Ejemplares similares

Linaclotide in Chronic Idiopathic Constipation Patients with Moderate to Severe Abdominal Bloating: A Randomized, Controlled Trial
por: Lacy, Brian E., et al.
Publicado: (2015)

A 12-Week, Randomized, Controlled Trial With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Linaclotide in Irritable Bowel Syndrome With Constipation
por: Rao, Satish, et al.
Publicado: (2012)

Responders vs clinical response: a critical analysis of data from linaclotide phase 3 clinical trials in IBS-C
por: Lacy, B E, et al.
Publicado: (2014)

Low-Dose Linaclotide (72 μg) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial
por: Schoenfeld, Philip, et al.
Publicado: (2018)

The PAC‐SYM questionnaire for chronic constipation: defining the minimal important difference
por: Yiannakou, Y., et al.
Publicado: (2017)

Linaclotide: A New Option for the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation in Adults
por: Parker, Colleen H., et al.
Publicado: (2013)

Rectal hyposensitivity: a common pathophysiological finding in patients with constipation and associated hypermobile Ehlers–Danlos syndrome
por: Choudhary, Anisa, et al.
Publicado: (2022)

Pharmacotherapy patterns in patients with chronic idiopathic constipation beginning treatment with linaclotide or lubiprostone in the United States
por: Nag, Arpita, et al.
Publicado: (2020)

Review article: linaclotide for the management of irritable bowel syndrome with constipation
por: Layer, P, et al.
Publicado: (2014)

Linaclotide induces secretion of cGMP from mouse colonic epithelium
por: Tchernychev, Boris, et al.
Publicado: (2013)

Linaclotide: evidence for its potential use in irritable bowel syndrome and chronic constipation
por: Lee, Noel, et al.
Publicado: (2012)

UK clinical experience up to 52 weeks with linaclotide for irritable bowel syndrome with constipation
por: Yiannakou, Yan, et al.
Publicado: (2018)

High‐dose linaclotide is effective and safe in patients with chronic constipation: A phase III randomized, double‐blind, placebo‐controlled study with a long‐term open‐label extension study in Japan
por: Fukudo, Shin, et al.
Publicado: (2018)

Assessment of treatment response in chronic constipation clinical trials
por: Ervin, Claire M, et al.
Publicado: (2014)

Diagnosis and treatment of irritable bowel syndrome with predominant constipation in the primary-care setting: focus on linaclotide
por: Chandar, Apoorva Krishna
Publicado: (2017)

Optimizing the Use of Linaclotide in Patients with Constipation-Predominant Irritable Bowel Syndrome: An Expert Consensus Report
por: Rey, Enrique, et al.
Publicado: (2017)

The Use of Linaclotide in Children with Functional Constipation or Irritable Bowel Syndrome: A Retrospective Chart Review
por: Baaleman, Desiree F., et al.
Publicado: (2021)

Randomized Trial of 2 Delayed-Release Formulations of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
por: Chey, William D., et al.
Publicado: (2021)

Efficacy of Prucalopride for Chronic Idiopathic Constipation: An Analysis of Participants With Moderate to Very Severe Abdominal Bloating
por: Staller, Kyle, et al.
Publicado: (2022)

Improving the Gastrointestinal Stability of Linaclotide
por: Braga Emidio, Nayara, et al.
Publicado: (2021)

Comparison of the Efficacy and Safety of Different Doses of Linaclotide for Patients with Chronic Constipation: A Meta-Analysis and Bayesian Analysis
por: Yang, Jiao, et al.
Publicado: (2021)

Linaclotide Reduced Response Time for Irritable Bowel Syndrome With Constipation Symptoms: Analysis of 4 Randomized Controlled Trials
por: Brenner, Darren M., et al.
Publicado: (2023)

Efficacy and safety of linaclotide in patients with irritable bowel syndrome with constipation: Chinese sub‐cohort analysis of a phase III, randomized, double‐blind, placebo‐controlled trial
por: Peng, Li Hua, et al.
Publicado: (2022)

Linaclotide for treating patients with irritable bowel syndrome with predominant constipation: a multicentre study of real-world data in China
por: Liu, Lan, et al.
Publicado: (2022)

Polyethylene Glycol 3350 in the Treatment of Chronic Idiopathic Constipation: Post hoc Analysis Using FDA Endpoints
por: Menees, Stacy B., et al.
Publicado: (2022)

Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double‐blind, placebo‐controlled trials
por: Schoenfeld, P., et al.
Publicado: (2014)

Linaclotide for the treatment of refractory lower bowel manifestations of systemic sclerosis
por: Dein, Eric J., et al.
Publicado: (2021)

Randomised clinical trial: linaclotide vs placebo—a study of bi‐directional gut and brain axis
por: Rao, Satish S.C., et al.
Publicado: (2020)

Clinical response to linaclotide at week 4 predicts sustained response in irritable bowel syndrome with constipation and improvements in digestive and extra-digestive symptoms
por: Serrano-Falcón, Blanca, et al.
Publicado: (2019)

Efficacy and safety of linaclotide for opioid-induced constipation in patients with chronic noncancer pain syndromes from a phase 2 randomized study
por: Brenner, Darren M., et al.
Publicado: (2020)

Multicentre, non-interventional study of the efficacy and tolerability of linaclotide in the treatment of irritable bowel syndrome with constipation in primary, secondary and tertiary centres: the Alpine study
por: Pohl, Daniel, et al.
Publicado: (2019)

Exploratory, multicenter, open-label study to evaluate the effects of linaclotide in patients with chronic constipation with an insufficient response to magnesium oxide: A study protocol
por: Yoshihara, Tsutomu, et al.
Publicado: (2022)

Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial
por: Chey, William D, et al.
Publicado: (2017)

Long-Term Safety and Effectiveness of Lubiprostone, a Chloride Channel (ClC-2) Activator, in Patients with Chronic Idiopathic Constipation
por: Lembo, Anthony J., et al.
Publicado: (2011)

A New Regioselective Synthesis of the Cysteine-Rich Peptide Linaclotide
por: Qiu, Zhonghao, et al.
Publicado: (2023)

Critical role of down-regulated in adenoma bicarbonate transporter in linaclotide stimulated intestinal bicarbonate secretion
por: Sarthi, Jessica B., et al.
Publicado: (2023)

Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1)
por: Chey, William D., et al.
Publicado: (2020)

Effects of the vibrating capsule on colonic circadian rhythm and bowel symptoms in chronic idiopathic constipation
por: Rao, Satish S. C., et al.
Publicado: (2020)

Clarification of Linaclotide Pharmacology Presented in a Recent Clinical Study of Plecanatide
por: Busby, Robert W., et al.
Publicado: (2014)

Engineering of an Anti-Inflammatory Peptide Based on the Disulfide-Rich Linaclotide Scaffold
por: Cobos, Claudia, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_m05b2mkq6n4vb3rcm93hrij5f7